| Catalog No. | Size | Price (USD) |
| KIT11848-1 | 1 Kit (96 Tests) | $414.71 |
| KIT11848-5 | 5 Kit (96 Tests) | $1,747.71 |
| KIT11848-48 | 48 Tests | $266.60 |
General Information
| Product name | Human IL-2 ELISA Kit |
| Specificity | This assay recognizes both recombinant and natural Human IL2. |
| Conjugate | HRP |
| Shipping | This ELISA Kit is shipped at ambient temperature. |
| Storage | Unopened Kit: Store at 2 - 8℃ Opened/Reconstituted Reagents: Please refer to CoA |
| Assay type | Solid Phase Sandwich ELISA (quantitative) |
| Sample type | Serum,Cell supernatant,Plasma |
| Sensitivity | 2.18 pg/mL |
| Assay range | 18.75-1200 pg/mL |
| Materials provided | 1. 96 well microplate coated with Capture Antibody 2. Detection Antibody conjugated to HRP 3. Standards 4. Wash Buffer Concentrate 5. Dilution Buffer Concentrate 6. Color Reagent A 7. Color Reagent B 8. Stop Solution |
| Product overview | This Human IL-2 ELISA Kit is an enzyme-linked immunosorbent assay for the quantitative measurement of Human IL-2 protein in Serum,Cell supernatant,Plasma . It contains recombinant Human IL-2, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use. |
| Interference | Preparations of the factors listed below at 50 ng/mL in a mid-range recombinant human IL2 control were assayed for interference. No significant interference was observed. |
Synonyms: IL-2 ELISA Kit, Human; lymphokine ELISA Kit, Human; TCGF ELISA Kit, Human
Image / Experimental Information
| Image 1 Description | This standard curve is only for demonstration purposes. A standard curve should be generated for each assay. |
| Image 1 Alt Text | Human IL2 ELISA Kit Standard Curve 23910 |
| Image 1 URL | Source image |
| Image 2 Description | This standard curve is only for demonstration purposes. A standard curve should be generated for each assay. |
| Image 2 Alt Text | Human IL2 ELISA Kit Specificity 23911 |
| Image 2 URL | Source image |
Background Information
| Full Name | interleukin 2 |
| Description | Interleukin-2, also known as a T-cell growth factor, TCGF, and IL2, is a secreted protein that belongs to the IL-2 family. Interleukin-2 / IL-2 was the first interleukin molecule to be discovered. Interleukin-2 / IL-2 molecule was first purified to homogeneity by immunoaffinity chromatography by Kendall Smith and his team at Dartmouth Medical School. Interleukin-2 / IL-2 was also the first cytokine shown to mediate its effects via a specific IL-2 receptor, and it was also the first interleukin to be cloned and expressed from a complementary DNA (cDNA) library. Interleukin-2 / IL-2 was designated number 2 because Smith's data at the time indicated that IL-1, produced by macrophages, facilitates IL-2 production by T lymphocytes (T cells). Interleukin-2 / IL-2 is produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Interleukin-2 / IL-2 is normally produced by the body during an immune response. When environmental substances (molecules or microbes) gain access to the body, these substances (termed antigens) are recognized as foreign by antigen receptors that are expressed on the surface of lymphocytes. Antigen binding to the T cell receptor (TCR) stimulates the secretion of Interleukin-2 / IL-2 and the expression of IL-2 receptors IL-2R. The IL-2 / IL-2R interaction then stimulates the growth, differentiation, and survival of antigen-selected cytotoxic T cells via the activation of the expression of specific genes. Interleukin-2 / IL-2 can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells. The World Reference Standard for Interleukin-2 / IL-2 is produced by the National Institute of Biological Standards and Control in the UK. A recombinant form of Interleukin-2 / IL-2 for clinical use is manufactured by Chiron Corporation. It has been approved by the Food and Drug Administration (FDA) for the treatment of cancers (malignant melanoma, renal cell cancer), and is in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The use of Interleukin-2 / IL-2 in HIV therapy is ineffective. |
| Research Areas |
|
| Related Pathways |
|
| Tags |
|
| References |
|
